Babu™ is proud to officially announce its investment and ongoing partnership with the American Gene Technologies (AGT) – one of the world’s finest gene therapy biotechnology companies. Using a “proprietary gene delivery platform to rapidly develop patented gene and cell therapies”, AGT has created a working platform of genetic tools and components to cure HIV, phenylketonuria (PKU), and liver cancer. With their revolutionary gene therapy platform, the potential to save millions of lives from once incurable diseases becomes unlocked. This is the future of our decade that Babu™ brings to your home. Together we will bring you longer, healthier, and better lives!
To learn more on how Babu™ and AGT envision their future together you shall read this statement of future partnership.
Telocyte’s founder and president, Michael Fossel, has recently published a highly influential paper in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association which was called by the editors as “the most important article we have ever published.” The paper already has had more than 300 requests for reprints. This article not only explains why telomere- based theories of ageing are the future in modern biogerontology, but also delivers the most up- to-date characterization of pathophysiology of Alzheimer’s disease (AD). Telocyte’s gene therapy developed for AD, and supported by Babu™, can be better understood with the rationale within Dr. Fossel’s article that can be found here.